stem
cell
transplant
sct
known
cur
treatment
mani
patient
lifethreaten
hematolog
solid
tumor
malign
likewis
solid
organ
transplant
sot
provid
lifesav
treatment
mani
patient
endstag
organ
diseas
approxim
sct
sot
procedur
perform
year
unit
state
patient
constant
risk
opportunist
infect
drugrel
pulmonari
toxic
malign
due
chronic
state
immun
suppress
aim
chapter
review
infecti
noninfecti
pulmonari
complic
stem
cell
solid
organ
transplant
focu
diagnost
therapeut
challeng
present
patient
despit
effect
prophylaxi
strategi
infect
lower
respiratori
tract
remain
common
lifethreaten
complic
risk
infect
primarili
determin
epidemiolog
exposur
donor
recipi
net
state
immun
suppress
spectrum
microorgan
respons
posttransplant
infect
similar
among
sct
sot
recipi
infect
follow
fairli
characterist
pattern
figur
show
timelin
pulmonari
complic
infecti
noninfecti
follow
sct
sot
respect
first
phase
infect
risk
consid
first
month
transplant
sct
recipi
infecti
risk
first
month
due
neutropenia
immun
suppress
relat
develop
acut
graftversushost
diseas
gvhd
treatment
convent
nosocomi
infect
gramposit
gramneg
bacteria
well
herp
simplex
viru
hsv
candida
speci
predomin
sot
recipi
first
month
posttransplant
infecti
risk
predominantli
relat
surgeri
intens
care
along
initi
immunosuppress
therapi
second
phase
infect
risk
extend
month
period
maximum
immunosuppress
prescrib
treat
gvhd
sct
patient
avoid
acut
allograft
reject
sot
recipi
interv
character
emerg
opportunist
pathogen
third
phase
infect
risk
month
immunosuppress
therapi
decreas
major
patient
infect
phase
predominantli
due
communityacquir
organ
lesser
extent
opportunist
pathogen
previous
common
pathogen
pneumocysti
jirovecii
pcp
cytomegaloviru
cmv
less
common
due
routin
use
antimicrobi
prophylaxi
howev
prophylact
antimicrobi
nosocomi
exposur
contribut
emerg
antimicrobialresist
pathogen
stenotrophomona
speci
mucormycosi
ganciclovirresist
cmv
addit
improv
microbiolog
diagnost
techniqu
allow
recognit
previous
undiagnos
infect
lung
lead
site
infect
lung
heart
transplant
recipi
second
common
site
liver
transplant
recipi
retrospect
multicent
studi
lung
transplant
recipi
pneumonia
report
recipi
microbiolog
etiolog
establish
case
microbiolog
proven
case
bacteri
fungal
due
virus
given
broad
spectrum
pathogen
caus
pneumonia
transplant
recipi
potenti
complic
empir
antibiot
import
identifi
caus
organ
whenev
possibl
bronchoscopi
procedur
choic
transplant
recipi
diagnost
yield
bronchoscopi
sct
recipi
report
rang
highest
perform
initi
antimicrobi
within
hour
present
likewis
sot
recipi
diagnost
yield
bronchoscopi
rang
highest
perform
pulmonari
opac
within
first
month
transplant
recommend
laboratori
evalu
bronchoscop
specimen
specif
pathogen
lower
respiratori
tract
transplant
recipi
list
etabl
bacteri
pneumonia
transplant
either
nosocomi
commun
acquir
mode
characterist
time
onset
caus
organ
e
sct
efig
cmv
infect
tradit
develop
within
first
month
sct
sot
howev
use
antivir
prophylaxi
delay
onset
prophylaxi
discontinu
current
guidelin
diagnosi
manag
cmv
sct
sot
recipi
support
use
either
detect
antigen
via
immunoassay
quantit
polymeras
chain
reaction
pcr
recognit
cmv
infect
serum
bronchoalveolar
lavag
bal
two
accept
strategi
prevent
cmv
diseas
transplant
recipi
univers
prophylaxi
antivir
administ
posttransplant
patient
risk
preemptiv
therapi
atrisk
patient
monitor
viral
replic
antivir
initi
predetermin
level
viru
replic
sct
sot
recipi
vulner
two
categori
viral
infect
opportunist
virus
especi
herpesvirus
communityacquir
respiratori
virus
opportunist
virus
respons
pulmonari
diseas
posttransplant
includ
cmv
hsv
varicella
zoster
viru
vzv
epsteinbarr
viru
ebv
era
earli
detect
prophylact
preemptiv
treatment
incid
cmv
pneumonia
lung
efig
liver
heart
less
kidney
efig
transplant
recipi
incid
rate
cmv
pneumonia
ribavirin
commonli
prescrib
rsv
infect
heart
lung
transplant
recipi
incid
influenza
infect
sct
mortal
rate
set
influenza
pneumonia
incid
influenza
lung
transplant
recipi
progress
lower
tract
infect
patient
influenza
infect
diagnos
nasal
wash
nasopharyng
swab
bal
rapid
antigen
detect
rtpcr
method
suscept
influenza
strain
treat
antivir
agent
amantadin
rimantadin
influenza
b
strain
treat
zanamivir
oseltamivir
oseltamivirresist
strain
influenza
found
transplant
patient
continu
shed
viru
therapi
infect
may
need
treat
investig
drug
current
develop
prolong
shed
influenza
viru
treatment
transplant
patient
also
mandat
close
attent
infect
control
procedur
prevent
spread
staff
patient
parainfluenza
piv
usual
serotyp
report
infect
sct
recipi
lower
respiratori
tract
involv
case
incid
parainfluenza
infect
lung
transplant
recipi
basi
transplantassoci
infect
surveil
network
transnet
incid
invas
fungal
infect
ifi
sot
recipi
order
decreas
frequenc
small
bowel
transplant
lung
liver
heart
pancrea
kidney
common
pathogen
invas
candidiasi
invas
aspergillosi
ia
efig
cryptococcu
nonaspergillu
mold
efig
endem
fungi
zygomycet
mortal
associ
candid
infect
sot
recipi
rang
highest
mortal
seen
liver
transplant
recipi
mortal
rate
ia
relat
type
transplant
rang
lung
transplant
heart
kidney
transplant
risk
factor
ifi
sot
recipi
includ
environment
exposur
use
highdos
steroid
antilymphocyt
therapi
viral
infect
particularli
cmv
infect
lung
transplant
hsv
diseas
develop
transplant
recipi
receiv
prophylaxi
hsv
commonli
reactiv
first
month
posttransplant
reason
recommend
hsvseroposit
transplant
recipi
receiv
least
week
antivir
prophylaxi
transplant
usual
acyclovir
clinic
pictur
hsv
pneumon
posttranspl
patient
rang
dyspnea
normal
radiograph
find
failur
wean
acut
respiratori
distress
syndrom
ard
direct
fluoresc
antibodi
test
real
time
pcr
assay
bal
sampl
provid
rapid
diagnosi
hsv
pneumonia
treat
iv
acyclovir
mgkg
everi
hour
hsv
diseas
lifethreaten
reduct
immunosuppress
consid
foscarnet
recommend
treatment
acyclovirresist
hsv
although
infrequ
problem
transplant
patient
vzv
report
rare
usual
late
caus
pneumonia
transplant
recipi
typic
present
vesicular
rash
preced
respiratori
symptom
iv
acyclovir
mgkg
iv
everi
hour
treatment
choic
communityacquir
respiratori
virus
carv
common
caus
infect
sct
sot
carv
includ
respiratori
syncyti
viru
rsv
influenza
metapneumoviru
mpv
parainfluenza
serotyp
peak
primarili
winter
month
parainfluenza
serotyp
adenoviru
present
year
round
risk
factor
progress
upper
respiratori
tract
carv
infect
pneumonia
sct
recipi
includ
infect
earli
transplant
allogen
sct
myeloabl
condit
gvhd
lymphopenia
risk
factor
progress
pneumonia
sot
recipi
well
defin
howev
mostimmunosuppress
recipi
appear
greatest
risk
sever
diseas
poor
outcom
carv
infect
transplant
recipi
often
character
prolong
viral
shed
complic
coinfect
viral
bacteri
fungal
pathogen
addit
direct
effect
carv
infect
indirect
effect
includ
increas
risk
acut
chronic
reject
bronchiol
obliteran
lung
transplant
concurr
allograft
reject
nonlung
sot
recipi
incid
rsv
infect
sct
infect
involv
lower
respiratori
tract
mortal
rate
rang
set
pneumonia
incid
rsv
lung
transplant
recipi
mortal
rate
incid
liver
transplant
recipi
rsv
diseas
rang
mild
upper
respiratori
tract
infect
lifethreaten
pneumonia
sensit
method
diagnos
rsv
infect
symptomat
patient
revers
transcriptas
rt
pcr
assay
nasal
wash
bal
ribavirin
oral
iv
inhal
ribavirin
approv
treatment
rsv
pneumon
sct
recipi
may
combin
iv
immunoglobulin
iv
palivizumab
human
monoclon
antibodi
rsv
use
prophylaxi
although
control
studi
ribavirin
therapi
sot
recipi
inhal
current
data
support
use
antifung
prophylaxi
either
azol
antifung
agent
liposom
amphotericin
b
sot
recipi
topic
discuss
chapter
mucormycosi
emerg
import
ifi
account
ifi
sct
see
efig
sot
see
efig
recipi
respect
often
late
complic
month
transplant
pulmonari
involv
half
case
overal
mortal
rate
among
sot
recipi
sct
recipi
mortal
least
firstlin
therapi
liposom
amphotericin
b
least
week
extens
earli
surgic
debrid
combin
liposom
amphotericin
echinocandin
may
consid
case
refractori
firstlin
therapi
pneumocysti
jirovecii
previous
pneumocysti
carinii
remain
potenti
lifethreaten
infect
sct
sot
develop
recipi
absenc
prophylaxi
attribut
mortal
risk
infect
greatest
first
month
transplant
decreas
significantli
year
patient
except
lung
transplant
recipi
clinic
present
includ
progress
dyspnea
cough
fever
hypoxemia
chest
radiograph
typic
show
bilater
abnorm
includ
perihilar
interstiti
alveolar
opac
nodul
cystic
lesion
pneumothorax
diagnosi
pcp
confirm
morpholog
identif
pneumocysti
organ
induc
sputum
bal
fluid
tissu
firstlin
therapi
pcp
highdos
trimethoprimsulfamethoxazol
combin
corticosteroid
trimethoprim
induc
cytochrom
activ
lead
decreas
serum
concentr
cyclosporin
transplant
center
use
lowdos
tmp
smx
pcp
prophylaxi
discontinu
year
group
except
lung
transplant
recipi
continu
indefinit
endem
fungal
infect
efi
blastomycosi
see
efig
histoplasmosi
develop
less
sct
sot
recipi
median
time
transplant
onset
efi
month
rang
month
although
case
diagnos
year
transplant
lung
common
site
infect
report
efi
case
howev
diseas
dissemin
half
sot
recipi
posttranspl
patient
diseas
blastomycosi
histoplasmosi
attribut
mortal
respect
incid
posttranspl
coccidioidomycosi
era
target
prophylaxi
less
howev
rate
dissemin
mortal
high
respect
coccidioid
serolog
uncertain
util
posttranspl
recipi
due
low
sensit
although
transplant
recipi
clearli
increas
risk
infect
patient
also
patient
particular
risk
fungal
infect
anastomot
site
incid
ia
infect
sct
efig
also
see
fig
rang
depend
stem
cell
sourc
condit
regimen
mortal
month
time
ia
diagnosi
rang
autolog
recipi
unrel
donor
recipi
differ
earlyversu
lateonset
infect
aspergillu
infect
present
posttransplant
patient
airway
colon
tracheobronch
pulmonari
aspergillosi
sinus
dissemin
diseas
symptom
invas
pulmonari
aspergillosi
includ
dyspnea
fever
product
cough
chest
pain
hemoptysi
howev
transplant
recipi
may
respiratori
symptom
recoveri
neutropenia
allogen
sct
recipi
invas
filament
fungal
infect
present
dyspnea
febril
diagnost
strategi
vari
cultur
remain
gold
standard
diagnosi
candida
infect
similarli
gold
standard
diagnosi
ia
biopsi
cultur
set
compat
clinic
radiograph
featur
although
altern
approach
includ
serolog
molecular
test
sct
recipi
serum
galactomannan
assay
sensit
specif
respect
diagnosi
ia
contrast
sot
recipi
serum
galactomannan
assay
uncertain
util
sensit
specif
respect
compar
serum
bal
appear
higher
specif
galactomannan
test
bal
sensit
specif
pcrbase
method
detect
aspergillu
yet
standard
clinic
use
although
publish
studi
indic
bal
analysi
use
quantit
rtpcr
sensit
specif
treatment
ifi
transplant
recipi
base
isol
pathogen
hospitalspecif
suscept
pattern
patient
clinic
condit
gabardi
colleagu
review
potenti
pathogenspecif
treatment
option
gener
twoprong
approach
advis
reduct
level
immunosuppress
extent
possibl
use
appropri
antifung
agent
import
recogn
clinic
relev
azol
antimicrobi
inhibit
cytochrom
isoenzym
activ
vari
degre
result
increas
serum
concentr
cyclosporin
tacrolimu
sirolimu
everolimu
could
lead
neurotox
andor
nephrotox
see
etabl
voriconazol
agent
choic
treatment
ia
base
superior
efficaci
surviv
benefit
comparison
amphotericin
howev
voriconazol
contraind
patient
receiv
sirolimu
liposom
amphotericin
b
altern
patient
azol
intoler
echinocandin
caspofungin
micafungin
anidulafungin
also
option
treatment
ai
low
potenti
drug
interact
although
may
lower
tacrolimu
level
surgic
resect
invas
pulmonari
aspergillosi
reason
option
neutropen
patient
inhal
liposom
amphotericin
b
use
treatment
aspergillu
tracheobronch
fig
incid
lung
transplant
recipi
treatment
primarili
support
care
includ
lowstretch
ventil
strategi
avoid
excess
fluid
administr
detail
discuss
pgd
present
chapter
sct
patient
spectrum
noninfecti
pulmonari
complic
develop
earli
posttransplant
period
fall
categori
idiopath
pneumonia
syndrom
ip
ip
broadli
defin
widespread
alveolar
injuri
seen
sct
absenc
activ
lower
respiratori
tract
infect
cardiac
dysfunct
acut
renal
failur
iatrogen
fluid
overload
efig
ip
encompass
spectrum
clinic
present
thought
result
varieti
lung
insult
includ
toxic
effect
sct
condit
regimen
immunolog
cellmedi
injuri
inflammatori
cytokin
occult
pulmonari
infect
cumul
incid
ip
allogen
sct
rang
follow
nonmyeloabl
condit
experi
noninfecti
pulmonari
complic
noninfecti
complic
attribut
pulmonari
toxic
chemoradi
therapi
use
prepar
regimen
associ
immunosuppress
medic
postop
surgic
complic
alloreact
lung
injuri
due
allograft
reject
gvhd
result
malign
impact
lung
see
fig
etabl
describ
common
complic
immedi
postop
period
individu
compon
chemotherapi
regimen
use
sct
associ
pulmonari
toxic
carmustin
bischloroethylnitrosourea
bcnu
use
singl
agent
combin
autolog
sct
solid
tumor
hematolog
malign
associ
acuteonset
pneumon
incid
prior
mediastin
radiat
therapi
bcnu
dose
greater
mg
age
younger
independ
risk
factor
develop
pneumon
autolog
sct
lymphoma
mechan
bcnuassoci
pulmonari
toxic
entir
elucid
thought
includ
oxid
stress
glutathion
dysfunct
immunemedi
lung
injuri
cyclophosphamid
anoth
agent
use
combin
total
bodi
radiat
chemotherapi
agent
prepar
regimen
autolog
allogen
sct
associ
pulmonari
toxic
thought
relat
increas
reactiv
oxygen
speci
gener
deplet
glutathion
store
pulmonari
toxic
associ
chemotherapeut
agent
radiat
discuss
elsewher
text
postop
respiratori
failur
well
describ
transplant
literatur
earli
caus
mortal
liver
transplant
incid
postop
respiratori
failur
report
singlecent
retrospect
studi
liver
transplant
recipi
caus
postop
respiratori
failur
pneumonia
pulmonari
edema
acut
lung
injuri
ali
ard
neurolog
dysfunct
immedi
posttransplant
period
common
risk
factor
noncardiogen
pulmonari
edema
includ
reperfus
syndrom
transfusionrel
acut
lung
injuri
trali
sepsi
pneumonia
gastric
aspir
acut
allograft
reject
kidney
cardiac
transplant
periop
respiratori
failur
less
common
singlecent
retrospect
studi
periop
respiratori
failur
identifi
kidney
transplant
recipi
similarli
heart
transplant
low
risk
respiratori
failur
retrospect
singlecent
studi
lenner
associ
cardiac
transplant
recipi
develop
respiratori
failur
posttransplant
episod
first
month
lung
transplant
respiratori
failur
earli
postop
period
commonli
result
infect
primari
graft
dysfunct
pgd
pgd
form
acut
lung
injuri
aris
within
hour
lung
transplant
sever
form
ischemiareperfus
injuri
clinic
spectrum
ip
encompass
sever
descript
form
lung
dysfunct
one
subset
term
diffus
alveolar
hemorrhag
dah
also
call
acut
pulmonari
hemorrhag
fig
video
hemorrhag
alveol
dah
gener
develop
immedi
posttranspl
period
character
progress
dyspnea
cough
hypoxemia
without
fever
cumul
incid
dah
sct
patient
median
time
onset
day
rang
day
allogen
recipi
day
rang
day
autolog
patient
diagnosi
dah
base
progress
bloodier
return
bal
fluid
see
fig
treatment
dah
consist
aggress
platelet
support
maintain
platelet
count
greater
equal
highdos
system
corticosteroid
mgkgday
gm
day
addit
aminocapro
acid
recombin
factor
vii
may
improv
outcom
despit
intervent
mortal
dah
rang
death
usual
due
multiorgan
failur
within
week
diagnosi
periengraft
respiratori
distress
syndrom
perd
anoth
clinic
subset
ip
perd
definit
develop
within
day
engraft
account
ip
case
allogen
sct
efig
video
follow
convent
fullintens
radiat
contain
prepar
regimen
median
time
onset
allogen
sct
day
rang
day
mortal
rate
rang
overal
greater
patient
requir
mechan
ventil
although
ip
also
develop
autolog
sct
incid
lower
median
time
onset
gener
later
day
rang
day
respons
corticosteroid
usual
prompt
prognosi
favor
compar
ip
allogen
sct
recipi
risk
factor
ip
allogen
sct
includ
fullintens
condit
total
bodi
irradi
acut
gvhd
older
recipi
age
underli
diagnosi
acut
leukemia
myelodysplast
syndrom
risk
factor
ip
follow
autolog
sct
includ
older
patient
age
sever
oral
mucos
condit
regimen
use
total
bodi
irradi
bcnu
chest
irradi
within
week
transplant
femal
gender
underli
diagnosi
solid
tumor
current
standard
treatment
strategi
ip
includ
broadspectrum
antibiot
iv
corticosteroid
support
care
lung
protect
mechan
ventil
venoven
ultrafiltr
respiratori
failur
respons
corticosteroid
mgkgday
shown
mix
efficaci
allogen
sct
recipi
like
reflect
divers
underli
caus
respons
lung
insult
compar
lower
dose
higher
dose
corticosteroid
therapi
mgkgday
shown
improv
outcom
associ
increas
complic
includ
fungal
infect
prophylaxi
filament
fungal
infect
voriconazol
micafungin
recommend
treatment
corticosteroid
mgkgday
fungal
pneumonia
identifi
ip
patient
time
autopsi
singlecent
studi
preclin
clinic
studi
suggest
neutral
tumor
necrosi
factor
tnf
may
use
thera
spectrum
druginduc
lung
diseas
report
transplant
associ
immunosuppress
therapi
implic
immunosuppress
agent
pattern
pulmonari
toxic
list
etabl
monoclon
antibodi
use
induct
immunosuppress
therapi
sot
infrequ
associ
pulmonari
toxic
infus
produc
cytokin
releas
syndrom
thought
transient
activ
cell
undergo
cell
lysi
clinic
manifest
syndrom
fever
chill
headach
dyspnea
myalgia
hypotens
result
pulmonari
edema
intraallograft
thrombosi
basiliximab
link
sever
noncardiogen
pulmonari
edema
within
hour
infus
alemtuzumab
associ
dah
offlabel
use
rituximab
part
induct
immunosuppress
regimen
renal
transplant
also
report
result
cytokin
releas
syndrom
ard
dah
develop
within
hour
administr
addit
pattern
rituximabinduc
lung
injuri
includ
interstiti
pneumon
cryptogen
organ
pneumonia
develop
within
week
administr
case
complet
resolv
discontinu
therapi
without
corticosteroid
iv
oral
cyclosporin
given
liver
kidney
bone
marrow
transplant
report
caus
noncardiogen
pulmonari
edema
ard
resolv
medic
discontinu
reaction
postul
idiosyncrat
mammalian
target
rapamycin
mtor
inhibitor
sirolimu
everolimu
bind
rapamycinfkbind
inhibit
b
lymphocyt
prolifer
induct
longterm
mainten
immunosuppress
pulmonari
toxic
report
sot
recipi
receiv
sirolimu
pulmonari
toxic
develop
within
month
initi
sirolimu
therapi
case
within
month
recipi
clinic
present
includ
cough
fatigu
fever
dyspnea
hemoptysi
physic
examin
notabl
hypoxemia
inspiratori
crackl
radiograph
find
ct
scan
includ
patchi
bilater
asymmetr
peripher
consolid
organ
pneumonialik
pattern
reticular
groundglass
opac
lobar
consolid
bal
report
show
lymphocyt
eosinophil
alveol
case
predomin
histolog
pattern
organ
pneumonia
pulmonari
hemorrhag
diffus
alveolar
damag
minor
case
pulmonari
alveolar
proteinosi
drug
discontinu
without
corticosteroid
mgkgday
mainstay
treatment
complet
resolut
symptom
within
month
less
sever
case
manag
reduct
sirolimu
dose
close
monitor
serum
level
howev
relaps
report
approach
sirolimu
also
thought
potent
antifibroprolif
agent
associ
sever
wound
heal
complic
lead
although
clinic
present
perd
sct
similar
subset
ip
lung
dysfunct
respons
corticosteroid
prognosi
better
delay
pulmonari
toxic
syndrom
dpt
also
fall
within
spectrum
ip
incid
dpt
autolog
sct
recipi
efig
receiv
chemotherapi
regimen
contain
bcnu
cyclophosphamid
cisplatin
median
time
onset
day
rang
day
treatment
corticosteroid
mgkgday
result
resolut
case
venou
thromboembol
vte
underrecogn
complic
sot
especi
lung
transplant
recipi
autopsi
seri
pulmonari
embol
diagnos
lung
heartlung
transplant
recipi
comparison
pulmonari
embol
diagnos
lung
transplant
recipi
antemortem
suggest
underdiagnosi
complic
renal
transplant
patient
incid
vte
rang
associ
advanc
renal
insuffici
acut
cmv
infect
cyclosporin
use
wherea
liver
transplant
patient
incid
pulmonari
embol
overal
cohort
heart
recipi
singl
center
patient
develop
vte
sct
patient
increas
risk
develop
vte
retrospect
studi
sct
recipi
incid
symptomat
vte
within
first
day
posttransplant
includ
incid
noncatheterassoci
lower
extrem
dvt
incid
pulmonari
embol
result
compar
smaller
retrospect
studi
sct
patient
median
time
sct
admiss
develop
noncatheterassoci
lower
extrem
dvt
day
pulmonari
embol
day
independ
risk
factor
develop
vte
prior
vte
gvhd
importantli
thrombocytopenia
partial
protect
develop
vte
safeti
efficaci
thromboprophylaxi
sct
patient
remain
uncertain
anticoagul
therapi
document
vte
accompani
platelet
transfus
maintain
platelet
count
l
greater
reduc
risk
bleed
complic
diaphragmat
dysfunct
develop
due
injuri
phrenic
nerv
perhap
hypothermia
mechan
damag
surgeri
incid
diaphragmat
dysfunct
heart
heartlung
transplant
report
lung
transplant
report
incid
diaphragmat
paralysi
among
liver
transplant
recipi
rang
attribut
right
phrenic
nerv
crush
injuri
time
suprahepat
vena
cava
clamp
diaphragmat
dysfunct
associ
significantli
increas
number
ventil
day
icu
length
stay
liver
heartlung
lungonli
transplant
recipi
compar
recipi
without
phrenic
nerv
damag
although
etiolog
bo
remain
uncertain
suspect
caus
immunemedi
injuri
lung
epithelium
due
allorecognit
lung
antigen
prospect
studi
treatment
airflow
obstruct
sct
given
presum
alloimmun
pathogenesi
bo
immunosuppress
therapi
remain
foundat
treatment
histor
clinic
approach
bo
treatment
highdos
system
corticosteroid
extend
period
time
month
howev
given
limit
respons
treatment
substanti
morbid
associ
highdos
system
corticosteroid
therapi
adjunct
approach
tri
includ
use
inhal
corticosteroid
azithromycin
montelukast
leukotrien
inhibitor
shown
efficaci
small
clinic
trial
bo
sct
emerg
therapi
bo
includ
extracorpor
photophoresi
blockad
infliximab
imatinib
statin
despit
aggress
treatment
bo
sct
poor
prognosi
overal
surviv
rate
year
year
lung
transplant
bo
develop
similar
clinic
manifest
histolog
characterist
bo
allogen
sct
recipi
howev
bo
much
common
lung
transplant
develop
lung
transplant
recipi
year
posttransplant
see
fig
detail
discuss
oblit
bronchiol
syndrom
lung
transplant
avail
chapter
sct
cop
infrequ
lateonset
noninfecti
complic
singlecent
retrospect
casecontrol
studi
freudenberg
colleagu
identifi
case
biopsyproven
cop
among
allogen
patient
smaller
retrospect
studi
cop
diagnos
allogen
sct
recipi
median
time
diagnosi
follow
sct
report
day
rang
day
patient
commonli
present
fever
dyspnea
nonproduct
cough
median
symptom
durat
day
rang
day
pipavath
associ
report
imag
featur
biopsyproven
cop
cohort
allogen
sct
recipi
ct
find
includ
groundglass
opac
consolid
fig
linear
opac
upper
lobe
predomin
pulmonari
physiolog
chang
associ
diagnosi
cop
predominantli
new
restrict
diffus
capac
abnorm
lesser
extent
new
obstruct
pattern
bronchoscopi
bal
recommend
rule
lower
respiratori
tract
infect
establish
diagnosi
cop
bal
character
lymphocytosi
lymphocyt
decreas
ratio
unlik
bronchiol
obliteran
cop
usual
diagnos
bronchoscop
biopsi
although
vat
may
requir
case
present
atyp
featur
histolog
characterist
includ
patchi
fill
respiratori
bronchiol
alveolar
duct
peribronchiolar
sac
polypoid
mass
granul
tissu
widen
alveolar
septa
infiltr
mononuclear
cell
accumul
foami
macrophag
within
alveoli
see
fig
associ
high
rate
bronchial
anastomosi
dehisc
lung
transplant
consequ
sirolimu
administr
start
month
transplant
bronchial
wound
heal
complet
everolimu
deriv
sirolimu
associ
pulmonari
toxic
heart
transplant
recipi
clinic
radiograph
histolog
featur
similar
report
sirolimu
allogen
sct
recipi
lateonset
noninfecti
pulmonari
complic
report
oblit
bronchiol
also
call
bronchiol
obliteran
syndrom
bo
cryptogen
organ
pneumonia
cop
formerli
call
bronchiol
obliteran
organ
pneumonia
boop
two
lateonset
noninfecti
pulmonari
complic
allogen
sct
strongli
associ
gvhd
clinic
hallmark
bo
develop
newonset
fix
airflow
obstruct
patholog
character
progress
circumferenti
fibrosi
termin
bronchiol
histor
incid
bo
sct
rang
depend
definit
airflow
obstruct
use
studi
attempt
standard
definit
bo
sct
clinic
research
purpos
nation
institut
health
chronic
gvhd
consensu
project
publish
diagnost
criteria
defin
bo
five
characterist
forc
expiratori
volum
second
fev
less
predict
fev
forc
vital
capac
fvc
ratio
less
evid
air
trap
small
airway
thicken
bronchiectasi
highresolut
comput
tomographi
efig
residu
volum
rv
greater
predict
patholog
confirm
constrict
bronchiol
absenc
respiratori
tract
infect
clinic
manifest
chronic
gvhd
least
one
organ
use
consensu
diagnost
criteria
singlecent
retrospect
studi
allogen
sct
recipi
au
colleagu
report
overal
preval
bo
among
transplant
patient
among
patient
chronic
gvhd
studi
median
time
transplant
diagnosi
bo
day
rang
day
bo
confer
increas
risk
death
diagnosi
multivari
analysi
cohort
sct
recipi
identifi
chronic
gvhd
lower
igg
level
ngdl
independ
risk
factor
develop
bo
onset
bo
usual
insidi
nonproduct
cough
dyspnea
wheez
although
histolog
evalu
lung
tissu
consid
gold
standard
diagnosi
bronchiol
obliteran
util
transbronchi
biopsi
limit
low
sensit
attribut
heterogen
lesion
small
biopsi
size
gener
invas
procedur
openlung
biopsi
videoassist
thorascop
vat
procedur
reserv
unusu
present
instanc
diagnosi
bo
base
presenc
persist
expiratori
airflow
obstruct
spirometri
absenc
caus
asthma
tobaccorel
emphysema
lower
respiratori
tract
infect
edema
normal
pulmonari
arteri
occlus
pressur
howev
lung
biopsi
confirm
diagnosi
presenc
extens
diffus
intim
prolifer
fibrosi
pulmonari
venul
treatment
consist
highdos
corticosteroid
methylprednisolon
mgkg
day
anecdot
success
overal
prognosi
pvod
sct
remain
poor
pulmonari
cytolyt
thrombu
pct
anoth
noninfecti
pulmonari
complic
involv
pulmonari
vasculatur
seen
exclus
allogen
sct
recipi
almost
alway
children
incid
pct
report
rang
median
onset
month
rang
month
transplant
clinic
manifest
includ
fever
cough
respiratori
distress
ct
find
rang
small
peripher
nodul
diffus
opac
diagnosi
requir
lung
biopsi
character
vascular
occlus
distal
pulmonari
vessel
entrap
leukocyt
endotheli
disrupt
infarct
adjac
tissu
singlecent
retrospect
studi
grade
ii
iv
acut
chronic
gvhd
independ
risk
factor
develop
pct
treatment
pct
consist
system
corticosteroid
prednison
mgkgday
pulmonari
symptom
resolv
typic
within
week
follow
steroid
taper
week
strong
associ
acut
chronic
gvhd
well
respons
corticosteroid
therapi
suggest
pct
alloreact
lung
injuri
prognosi
pct
favor
report
death
attribut
entiti
pulmonari
metastat
calcif
wellknown
complic
chronic
renal
failur
rare
complic
acut
chronic
gvhd
subsequ
develop
cop
patient
cop
like
acut
gvhd
involv
skin
chronic
gvhd
involv
gut
oral
caviti
suggest
pathogenesi
least
part
relat
alloreact
lung
injuri
corticosteroid
therapi
standard
treatment
cop
sct
although
dose
durat
empir
deriv
histor
prednison
dose
mgkgday
prescrib
progress
decreas
total
durat
week
howev
order
limit
risk
iatrogen
complic
current
recommend
start
prednison
mgkgday
week
taper
total
week
possibl
conjunct
use
macrolid
prognosi
cop
sct
recipi
gener
favor
resolut
stabl
diseas
progress
cop
despit
corticosteroid
patient
die
respiratori
failur
patient
relaps
corticosteroid
taper
stop
treatment
typic
respond
reiniti
increas
dose
corticosteroid
therapi
pulmonari
venoocclus
diseas
pvod
rare
lateonset
complic
sct
present
insidi
onset
fatigu
exert
dyspnea
within
month
transplant
physic
examin
typic
show
hypoxemia
rest
tachycardia
consist
pulmonari
hypertens
right
heart
catheter
demonstr
elev
pulmonari
arteri
pressur
normal
pulmonari
capillari
wedg
pressur
angiographi
use
exclud
pulmonari
emboli
etiolog
pulmonari
hypertens
diagnosi
pvod
strongli
support
triad
pulmonari
arteri
hypertens
radiograph
evid
pulmonari
ptld
allogen
sct
report
case
overal
longterm
surviv
lower
sct
recipi
compar
sot
recipi
worst
patient
transplant
hematolog
malign
addit
inform
ptld
present
chapter
ks
soft
tissu
malign
associ
immunosuppress
sot
recipi
larg
populationbas
studi
among
recipi
incid
ks
per
personyear
median
time
transplant
ks
year
risk
factor
develop
ks
posttransplant
unit
state
includ
male
gender
older
recipi
age
hispan
ethnic
nonu
citizenship
number
mismatch
hlab
locu
ks
develop
primarili
transplant
recipi
preexist
human
infect
twenti
percent
ks
case
organ
transplant
viscer
involv
includ
lung
pulmonari
complic
common
follow
stem
cell
solid
organ
transplant
incid
follow
characterist
pattern
risk
factor
develop
pulmonari
complic
vari
includ
type
organ
tissu
transplant
degre
durat
immunosuppress
preexist
lung
diseas
concomit
medic
administr
periop
insult
environment
exposur
infecti
etiolog
must
aggress
assess
often
requir
invas
lung
sampl
accur
diagnosi
promptli
treat
use
antimicrobi
prophylaxi
commonli
encount
pathogen
reduc
incid
certain
pulmonari
infect
transplant
recipi
howev
antimicrobi
prophylaxi
also
led
emerg
resist
pathogen
noninfecti
complic
transplant
seen
earli
includ
acut
respiratori
distress
syndrom
idiopath
pneumonia
syndrom
venou
thromboembol
diseas
diaphragmat
dysfunct
late
includ
druginduc
toxic
bronchiol
obliteran
syndrom
posttransplant
lymphoprolif
disord
renal
transplant
recipi
lesion
typic
nodular
opac
mm
diamet
may
unilater
diffus
predilect
upper
lobe
efig
patient
asymptomat
although
progress
lesion
may
lead
dyspnea
along
restrict
pattern
diffus
capac
abnorm
pulmonari
function
test
clinic
signific
pulmonari
metastat
calcif
distinguish
entiti
pulmonari
infect
malign
transplant
recipi
organ
transplant
associ
increas
risk
develop
malign
risk
factor
malign
includ
prolong
use
immunosuppress
therapi
infect
oncogen
virus
progress
age
transplant
recipi
longer
surviv
transplant
less
commonli
malign
cell
transmit
donor
tissu
transplantrel
malign
affect
lung
includ
nonhodgkin
lymphoma
bronchogen
carcinoma
posttransplant
lymphoprolif
disord
kaposi
sarcoma
ks
larg
populationbas
registri
linkag
studi
sot
recipi
incid
nonhodgkin
lymphoma
higher
transplant
recipi
compar
gener
popul
likewis
incid
lung
cancer
increas
lung
heart
liver
kidney
transplant
recipi
compar
gener
popul
discuss
lung
cancer
lung
transplant
recipi
see
chapter
posttransplant
lymphoprolif
disord
ptld
infrequ
seriou
complic
compos
heterogen
group
alter
bcell
monoclon
polyclon
prolifer
disord
develop
associ
immunosuppress
therapi
sot
incid
ptld
adult
vari
among
studi
gener
higher
lung
heartlung
heart
compar
liver
kidney
efig
recipi
incid
appear
bimod
distribut
lung
transplant
case
develop
within
first
month
transplant
risk
factor
develop
ptld
sot
includ
age
time
transplant
degre
immunosuppress
use
antilymphocyt
globulin
number
episod
acut
reject
seroneg
ebv
transplant
especi
ebvseroposit
donor
cmv
hepat
c
infect
allogen
sct
ptld
rare
seriou
complic
well
efig
multicent
studi
allogen
sct
recipi
overal
incid
ptld
case
diagnos
within
first
year
posttransplant
earlyonset
ptld
sct
risk
factor
includ
unrel
hla
mismatch
relat
donor
stem
cell
sourc
tcell
deplet
donor
marrow
use
antithymocyt
globulin
monoclon
antibodi
prophylaxi
treatment
acut
gvhd
lateonset
ptld
risk
factor
identifi
chronic
extens
gvhd
incid
ptld
increas
patient
two
risk
factor
three
risk
factor
pulmonari
involv
